Ra Pharmaceuticals has entered into a collaboration with Merck for the development of Cyclomimetics, a new class of compounds that have the diversity and specificity of antibodies while retaining the attributes of small molecules. Ra will use its Extreme Diversity platform to develop Cyclomimetic candidates for protein targets in multiple therapeutic areas.   Ra is eligible to receive as much as $200 million in payments, including upfront and research funding, as well as the achievement of disco...